• FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease

  On 15 May 2026, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) and atezolizumab and hyaluronidase-tqjs (···【Read More】

  Update: 12 Jun,2026Source: Haiou HealthViews: 76

• FDA approves Lilly's EBGLYSS (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

  June 9, 2026 — Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved a new dosing regimen for EBGLYSS (lebriki···【Read More】

  Update: 10 Jun,2026Source: Haiou HealthViews: 100

• Treat quality as life! BigBear Pharma protects life and health with hardcore quality

  In the pharmaceutical industry, quality is not only the lifeline of an enterprise but also the most solemn commitment to every patient. Since its esta···【Read More】

  Update: 09 Jun,2026Source: Haiou HealthViews: 99

• Ivosidenib (AIVODX) manufactured by Big Bear Pharma has been approved in Laos

  Vientiane, Laos - January 3, 2024 - BigBearPharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer the···【Read More】

  Update: 08 Jun,2026Source: Haiou HealthViews: 103

• Trelagliptin (TEGLIDX) produced by BigBear Pharma has been approved in Laos

  Vientiane, Laos - January 3, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on the development and commercialization of innovative···【Read More】

  Update: 08 Jun,2026Source: Haiou HealthViews: 96

• Autobahn accelerates toward pivotal clinical trials: Thyroid hormone mimetic relieves bipolar depression in phase 2 trial

  Elunetirom is a small molecule drug taken orally once daily. After six weeks of treatment, patients' depression severity decreased by an average o···【Read More】

  Update: 05 Jun,2026Source: Haiou HealthViews: 106

• With outstanding R&D and a commitment to universal access, Bigbear Pharmaceutical sets a new benchmark in healthcare

  In the field of healthcare, Dabear Pharmaceutical has always adhered to the初心 of "making good medicines accessible", and with deep R&D e···【Read More】

  Update: 04 Jun,2026Source: Haiou HealthViews: 106

• Selumetinib (SEMEDX) produced by BigBearPharma has been approved in Laos

  Vientiane, Laos - April 8, 2024 - BigBearPharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer thera···【Read More】

  Update: 04 Jun,2026Source: Haiou HealthViews: 107

• BigBear Pharma Announces Approval of Baricitinib (BARUDX) in Laos

  Vientiane, Laos - April 8, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on the development and commercialization of innovative c···【Read More】

  Update: 03 Jun,2026Source: Haiou HealthViews: 106

• FDA Approves Zaynich (cefepime and zidebactam) for the Treatment of Complicated Urinary Tract Infections

  May 30, 2026 – Wockhardt announced that the U.S. Food and Drug Administration (FDA) has approved Zaynich (cefepime and zidebactam), a novel intravenou···【Read More】

  Update: 03 Jun,2026Source: Haiou HealthViews: 108

• Laos Big Bear Pharma: A New Force in Generic Drugs Rising from the Heart of Southeast Asia

  On the banks of the Mekong River in Laos, a transformation in healthcare accessibility is quietly taking place. As the Lao government continues to inc···【Read More】

  Update: 02 Jun,2026Source: Haiou HealthViews: 110

• BigBear Pharma Announces Approval of Larotrectinib (LARODX) in Laos

  Vientiane, Laos - May 30, 2024 - BIGBEARPharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer therap···【Read More】

  Update: 02 Jun,2026Source: Haiou HealthViews: 109

• BigBear Pharma Announces Approval of Adagrasib (ADADX) in Laos

  Vientiane, Laos – July 14, 2024 – BigBear Pharma, a leading biopharmaceutical company focused on the development and commercialization of innovative c···【Read More】

  Update: 01 Jun,2026Source: Haiou HealthViews: 112

• EMA Recommends Extending Indications for Decitabine /Cedazuridine

  On 23 April 2026, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommendi···【Read More】

  Update: 01 Jun,2026Source: Haiou HealthViews: 110

• Big Bear Pharmaceuticals : New Power of Southeast Asian Generics, Quality for Global Health

  When it comes to generic drugs, the first label that comes to many people's minds might be "India." However, as the global pharmaceutica···【Read More】

  Update: 29 May,2026Source: Haiou HealthViews: 117